Compare Adaptive Biotechnologies Corp (ADPT) vs Amer Sports Inc (AS) Price & Performance

ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.

Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.

Amer Sports (AS) trades at $34.84, down 0.6% on the day, with a neutral technical outlook. The company reported strong Q1 2026 results, beating EPS estimates with $0.38 versus $0.31 expected, and raised full-year guidance. Revenue grew 32% year-over-year to $1.95 billion. Analyst sentiment is overwhelmingly positive, with 12 of 14 analysts rating it a Buy and a consensus price target of $56.00, implying significant upside. Operating cash flow remains robust at $729.80 million for 2025.

The outlook is favorable given consistent earnings beats and raised guidance, but risks include high valuation multiples (P/E of 43.54) and dependence on the Arc'teryx brand's sustained momentum. The stock presents a growth opportunity if execution continues, though premium valuation requires careful monitoring of margin trends and competitive pressures.